The International Foundation for Autoimmune & Autoinflammatory Arthritis has raised concerns about the rising costs in the federal 340B Drug Pricing Program, stating that these increases are not benefiting patients — an issue garnering attention in Pennsylvania. The organization has called for urgent reforms to enhance accountability and transparency, as reported in a statement on X.
The 340B Drug Pricing Program mandates pharmaceutical manufacturers to offer discounted outpatient drugs to eligible hospitals and clinics. However, multiple analyses indicate that a significant portion of these savings does not directly reduce patient out-of-pocket expenses. Critics argue that the program has deviated from its original purpose, with reform advocates emphasizing the need for clearer rules and reporting to ensure discounts reach patients who need them.
According to the Health Resources and Services Administration, drug purchases under the 340B program have surged from approximately $6.6 billion in 2010 to over $43.9 billion in 2021, indicating a substantial increase in program spending. Despite this growth, oversight mechanisms have not expanded proportionally, raising concerns about the integrity of the program. Experts caution that without robust audits and transparency measures, it remains uncertain how much of this expansion benefits safety-net patients.
PhRMA’s 2025 state profile shows Pennsylvania 340B hospitals spend on average only 1% of operating costs on charity care, with 92% below the national hospital average, while their assets rose 20% and charity care dropped 36% from 2014–2022. Employers pay an estimated $227M more in health costs due to 340B-related foregone rebates.
The International Foundation for Autoimmune & Autoinflammatory Arthritis (AiArthritis), a nonprofit organization focused on improving the lives of individuals with autoimmune arthritis diseases through education, advocacy, and patient-centered policy engagement, regularly participates in federal health policy discussions. Through research partnerships and patient-focused initiatives, AiArthritis amplifies community voices concerning access and affordability issues.
